GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Net Income Including Noncontrolling Interests

Conduit Pharmaceuticals (FRA:ZK7) Net Income Including Noncontrolling Interests : €-17.88 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Conduit Pharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €-4.76 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €-17.88 Mil.

Conduit Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Conduit Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
-3.24 -4.61 -0.49 -17.00

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.27 -5.00 -5.82 -2.30 -4.76

Conduit Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conduit Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
QLGN SCNI PTIX KTTA PCSA WINT THAR ALZN SPRB SXTP VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CDT:USA
Address
4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Website
https://www.conduitpharma.com
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines